Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21.

Claudia Giordano,Marco Picardi,Novella Pugliese,Annamaria Vincenzi,Davide Pio Abagnale,Laura De Fazio, Maria Luisa Giannattasio,Carmina Fatigati,Mauro Ciriello, Alessia Salemme,Giada Muccioli Casadei,Elena Vigliar,Massimo Mascolo,Giancarlo Troncone,Fabrizio Pane

Frontiers in oncology（2023）

引用 0|浏览25

暂无评分

摘要

This is the first study collecting data regarding a consistent and homogeneous large sample of 187 HBsAg-/HBcAb+ patients undergoing standard R-CHOP-21 for aggressive lymphoma. In our study, 24-month-long prophylaxis with LAM appears to be the most effective approach with a null risk of OBI reactivation, hepatitis flare-up, and ICHT disruption.

查看译文

关键词

R-CHOP-21,antiviral prophylaxis,chemotherapy disruption,non-hodgkin lymphoma,occult hepatitis B virus infection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要